Biomedical Research · us
Seeing Heart Failure Through Gene Switches: 750,000 Cells Reveal a Dysregulated Regulatory Network
By integrating single-cell molecular maps, chromatin structure, and genetic data, the research team charted how heart failure rewrites gene regulation across different cell types, while providing more precise coordinates for interpreting noncoding risk variants.
Heart failure is not the result of a single gene or one type of cell malfunctioning. As the heart muscle gradually loses its ability to pump blood, the balance among cardiomyocytes, fibroblasts, and immune cells also changes. A new study published in *Science* sought to reconstruct this process of dysregulation across the entire heart tissue at the level of the switches that control genes.
The research team analyzed the four chambers of the heart in 36 people with or without heart failure, integrating single-cell molecular features, DNA accessibility, and three-dimensional chromatin structure from more than 750,000 cells to identify 12 major cardiac cell types. Compared with non-failing hearts, diseased tissue contained more fibroblasts and immune cells and a lower proportion of cardiomyocytes, revealing an interplay between tissue remodeling and inflammatory responses.
The changes extended beyond cell numbers. The study showed that gene expression changed in more than 10,000 genes in failing hearts, while accessibility differed at more than 50,000 DNA regions, with the changes particularly pronounced in cardiomyocytes and fibroblasts. Whether a DNA region is open affects whether regulatory proteins can access gene switches; these differences therefore help trace which regulatory programs may be activated or shut down in disease.
Another use of this map is to provide biological anchors for genome-wide association studies. Many genetic variants associated with cardiovascular disease are located in regions that do not directly encode proteins, making it difficult in the past to determine which genes they affect. The team found that disease-risk variants were concentrated in regulatory regions of specific cell types and might act on candidate genes through long-range DNA contacts, connecting “risk coordinates” to more specific cells, genes, and pathways.
Such links can help researchers narrow the search for drug targets, but the map itself is not yet evidence of treatment efficacy. The study primarily presents associations and regulatory clues in diseased tissue, and causality cannot be established from gene-expression or chromatin changes alone. The sample also included only 36 people, and larger studies are still needed to verify whether the findings encompass differences in etiology, disease course, treatment background, and population.
The researchers also released code and data packages that can reproduce the analytical results, providing a foundation for subsequent testing of candidate pathways. Before the findings can truly lead to precision treatment, functional experiments are still needed to confirm which regulatory nodes drive disease progression and to assess whether intervening in specific cells affects other essential cardiac functions. The study information also discloses the authors’ conflicts of interest and a patent application filed by the researchers and the University of California San Diego, which should also be taken into account when interpreting the potential translational value.